OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,98 USD
arrow_upward
+1,12%(+0,055) 1D
16-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
5,05 USD
High
5,07 USD
Low
4,98 USD
Mkt. cap
1,20 трлн
Avg. vol.
62,80 миң
Volume
20,91 миң
52-wk high
5,75 USD
52-wk low
3,82 USD
Beta
0,21
Shares outstanding
1,50 млд
No. of employees
4 миң
Open
5,05 USD
High
5,07 USD
Low
4,98 USD
Mkt. cap
1,20 трлн
Avg. vol.
62,80 миң
Volume
20,91 миң
52-wk high
5,75 USD
52-wk low
3,82 USD
Beta
0,21
Shares outstanding
1,50 млд
No. of employees
4 миң
News stories
From web sources and news partners
CryptoRank
·
18 мүнөт мурун
The S&P 500 Is Near Record Highs: But Most Stocks Are Already in a Bear Market
MarketBeat
·
47 мүнөт мурун
Eikon Therapeutics (NASDAQ:EIKN) Stock Rating Raised to "Strong-Buy" at HC Wainwright
Simply Wall Street
·
50 мүнөт мурун
Surprised By Recursion Pharmaceuticals’ Slide? What Investors Overlooked
Yahoo Finance
·
5 саат мурун
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4,21 миң
Founded1717
HeadquartersOsaka, Osaka, Япония
SectorPharmaceutical industry
Websiteono-pharma.com